|Bid||122.46 x 800|
|Ask||122.94 x 1800|
|Day's Range||122.76 - 124.24|
|52 Week Range||121.28 - 148.32|
|PE Ratio (TTM)||259.30|
|Earnings Date||Jul 17, 2018|
|Forward Dividend & Yield||3.36 (2.57%)|
|1y Target Est||145.10|
The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.
Thus, the company has announced its plans to make some changes in its baby care product line and is set for a relaunch with a target of more naturally sourced products with recyclable packaging. The redesigned line is expected to launch in August. Johnson & Johnson is planning an end-to-end relaunch. Johnson & Johnson recognizes the need to make certain fundamental changes to its products after witnessing declining sales from its leading range of baby care products.
Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.
Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.
Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.
The Menlo Park company had already raised $1.2 billion; now it's adding $300 million, mainly from Chinese investors, as it aims to develop a simple blood test to discover cancers early.
In this daily bar chart of JNJ, below, we can see that prices for JNJ have been under selling pressure since late January. In the bottom panel is the 12-day price momentum study which shows a pattern of rising lows from February to March to April. In this weekly bar chart of JNJ, below, we have a mixed picture.
It’s been a bumpy ride so far this year for pharmaceutical giant Johnson & Johnson (NYSE:JNJ). Johnson & Johnson has been weighed down by poor sentiment in the healthcare space, legal troubles and worries about further government interference in the industry. One such concern has been Johnson & Johnson’s Baby Care unit.
A lot of large-cap familiar names are still called “blue-chip stock” when they are nothing of the kind. If you can’t rid the term “blue-chip stock” from your lexicon, then it should at least apply to a whole new stream of companies. “Blue-chip stock” used to refer to companies that were constantly growing earnings in the high single-digits or more in terms of percentage, had a fortress balance sheet and were constantly innovating.
Have you been keeping an eye on Johnson & Johnson’s (NYSE:JNJ) upcoming dividend of $0.9 per share payable on the 12 June 2018? Then you only have 3 days leftRead More...
NEW YORK, NY / ACCESSWIRE / May 21, 2018 / U.S. markets finished lower on Friday, and posted weekly drop as uncertainty on trade negotiations linger on the market. The Dow Jones Industrial Average was ...
Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...
In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.
H ealth workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said. Jessica Ilunga said 4,000 doses of vaccine were shipped on Saturday to Mbandaka, which last week registered the first cases in an urban area since the latest flare-up of the disease was announced earlier this month.
GENEVA/KINSHASA, May 18 (Reuters) - The Ebola outbreak in Democratic Republic of Congo can be brought under control and is not an international public health emergency, experts advising the World Health Organization said on Friday. Earlier in the day the WHO had said the first confirmation of Ebola in Mbandaka, a city of about 1.5 million people, had prompted it to declare a "very high" public health risk to the country and a "high" risk to the region.
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease. Some trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said http://www.janssen.com/update-janssens-bace-inhibitor-program Janssen, a unit of Johnson and Johnson. Atabecestat belongs to a class of experimental Alzheimer's drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.
As would-be parents push back parenthood and birth rates continue to decline companies that provide baby products are feeling the pinch.
Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.
Many exchange-traded funds that are viewed as “core” holdings are cap-weighted. Core funds that emphasize individual investment factors usually focus on growth or value with quality often left out of the ...
The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.